GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Translate Bio Inc (NAS:TBIO) » Definitions » Total Current Liabilities

Translate Bio (Translate Bio) Total Current Liabilities : $81.5 Mil (As of Jun. 2021)


View and export this data going back to 2018. Start your Free Trial

What is Translate Bio Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Translate Bio's total current liabilities for the quarter that ended in Jun. 2021 was $81.5

Translate Bio Total Current Liabilities Historical Data

The historical data trend for Translate Bio's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Translate Bio Total Current Liabilities Chart

Translate Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20
Total Current Liabilities
12.01 12.09 14.29 41.67 101.34

Translate Bio Quarterly Data
Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 51.77 124.02 101.34 118.02 81.51

Translate Bio Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Translate Bio's Total Current Liabilities for the fiscal year that ended in Dec. 2020 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=16.441+11.733
+Other Current Liabilities+Current Deferred Liabilities
=5.6+67.563
=101.3

Translate Bio's Total Current Liabilities for the quarter that ended in Jun. 2021 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=23.489+11.685
+Other Current Liabilities+Current Deferred Liabilities
=5.326+41.014
=81.5

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Translate Bio Total Current Liabilities Related Terms

Thank you for viewing the detailed overview of Translate Bio's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Translate Bio (Translate Bio) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Translate Bio Inc (NAS:TBIO) » Definitions » Total Current Liabilities
Comparable Companies
KNSA IMAB CYTK VCYT PHAT BEAM PTLA CRTX NGM RVNC OCSE:NOVO B ASX:CSL VRTX REGN XKRX:207940 SGEN MRNA ALXN XKRX:068270 INCY
Traded in Other Exchanges
N/A
Address
29 Hartwell Avenue, Lexington, MA, USA, 02421
Website
http://www.translate.bio
Translate Bio Inc is a clinical-stage mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, for the treatment of cystic fibrosis (CF) and MRT5201, for the treatment of ornithine transcarbamylase (OTC) deficiency.
Executives
Jean Francois Formela director C/O ATLAS VENTURE, 890 WINTER STREET, WALTHAM MA 02451
Renaud Ronald C Jr director, officer: Chief Executive Officer, other: President C/O IDENIX PHARMACEUTICALS, INC., 60 HAMPSHIRE STREET, CAMBRIDGE MA 02109
Paul D. Burgess officer: Chief Operating Officer, CLO, other: Secretary C/O TRANSLATE BIO, INC., 29 HARTWELL AVENUE, LEXINGTON MA 02421
Owen Hughes director C/O RADIUS HEALTH, INC., 201 BROADWAY, 6TH FLOOR, BOSTON MA 02139
Shire Human Genetic Therapies, Inc. 10 percent owner 300 SHIRE WAY LEXINGTON MA 02421
Takeda Pharmaceutical Co Ltd 10 percent owner 1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU, TOKYO M0 103-8668
Baupost Group Gp, L.l.c. 10 percent owner 10 ST. JAMES AVENUE, SUITE 1700, BOSTON MA 02116
Seth A Klarman 10 percent owner 10 ST JAMES AVENUE, STE 1700, BOSTON MA 02116
Baupost Group Llc/ma 10 percent owner 10 ST JAMES AVE, SUITE 1700, BOSTON MA 02116
George Demetri director BLUEPRINT MEDICINES CORP., 215 FIRST STREET, SUITE 340/350, CAMBRIDGE MA 02142
Daniella Beckman director C/O IDENIX PHARMACEUTICALS, INC., ONE KENDALL SQUARE, BLDG. 1400, CAMBRIDGE MA 02139
Robert M Plenge director C/O TRANSLATE BIO, INC., 29 HARTWELL AVENUE, LEXINGTON MA 02421
Daniel Lynch director
Robert J. Meyer director 2505 MERIDIAN PARKWAY, C/O CHIMERIX, INC, SUITE 100, DURHAM NC 27713
Ann Barbier officer: Chief Medical Officer 255 STATE STREET, C/O PIERIS PHARMACEUTICALS,INC., BOSTON MA 02109